Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Vaxxinity, Inc. VAXX
$2.00
-$0.13 (-6.54%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
264163565.00000000
-
week52high
6.20
-
week52low
1.24
-
Revenue
0
-
P/E TTM
-12
-
Beta
0.00000000
-
EPS
-0.58000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:39
Описание компании
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Evercore ISI Group | In-Line | 27 апр 2022 г. | |
| Jefferies | Buy | 07 дек 2021 г. | |
| B of A Securities | Buy | 06 дек 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Prime Movers Lab Fund I LP | D | 8764372 | 405217 | 23 янв 2023 г. |
| Prime Movers Lab Fund I LP | D | 2065027 | 95475 | 23 янв 2023 г. |
| Prime Movers Lab Fund I LP | D | 9169589 | 11121 | 02 дек 2022 г. |
| Prime Movers Lab Fund I LP | D | 2160502 | 2620 | 02 дек 2022 г. |
| Prime Movers Lab Fund I LP | D | 9180710 | 270964 | 01 дек 2022 г. |
| Prime Movers Lab Fund I LP | D | 2163122 | 63843 | 01 дек 2022 г. |
| Prime Movers Lab Fund I LP | D | 9451674 | 25243 | 06 сент 2022 г. |
| Prime Movers Lab Fund I LP | D | 1473100 | 3934 | 06 сент 2022 г. |
| Prime Movers Lab Fund I LP | D | 836499 | 2234 | 06 сент 2022 г. |
| Prime Movers Lab Fund I LP | D | 2226965 | 5947 | 06 сент 2022 г. |
Новостная лента
Why Shares of Vaxxinity Jumped This Week
The Motley Fool
19 янв 2023 г. в 14:04
Investors are hoping the company's COVID-19 vaccine will turn the company from a clinical-stage biotech to a commercial one.
Vaxxinity: Potential Strong Upsides Ahead
Seeking Alpha
17 янв 2023 г. в 07:58
We may not be at the end credits for COVID-19 virus. Shares of Vaxxinity, Inc., like most biotechs, have plummeted over the past year due to unprecedented market headwinds, both macroeconomic and geopolitical.
Why Shares of Vaxxinity Soared This Week
The Motley Fool
02 дек 2022 г. в 05:30
Positive news regarding a different company's Alzheimer's treatment may have helped Vaxxinity.